Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer

May 8th 2018

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

Monk Highlights Clinical Trials in Recurrent Ovarian Cancer

May 7th 2018

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer

May 5th 2018

Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.

Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian Cancer

April 27th 2018

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Managing Ovarian Cancer Patients in the Future

April 26th 2018

Therapy Selection in BRCA-Mutated Ovarian Cancer

April 26th 2018

Sequencing Therapies in Ovarian Cancer

April 26th 2018

PARP Inhibitor Selection in Ovarian Cancer

April 26th 2018

Additional Considerations: PARPs for EOC in Practice

April 26th 2018

PARP Inhibitors in Recurrent Ovarian Cancer

April 26th 2018

Secondary Debulking in Recurrent Ovarian Cancer

April 26th 2018

Bevacizumab in Recurrent Ovarian Cancer

April 26th 2018

Approaching Recurrent Ovarian Cancer

April 26th 2018

Biomarkers and Molecular Testing in Ovarian Cancer

April 26th 2018

I-O Therapy in Advanced Ovarian Cancer

April 26th 2018

Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

April 26th 2018

Bevacizumab in the Neoadjuvant Setting of EOC

April 26th 2018

Incorporating Bevacizumab into First-Line Practice for EOC

April 26th 2018

Upfront Bevacizumab in Advanced Ovarian Cancer

April 26th 2018

HIPEC in Advanced Ovarian Cancer

April 26th 2018